Emergent is developing therapies for Covid-19 prevention and treatment. Credit: Markus Spiske on Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Emergent BioSolutions has begun efforts to develop two plasma-derived product candidates to treat and prevent the new Covid-19 coronavirus infection.

The products will build on the company’s hyperimmune platforms.

Emergent notes that hyperimmunes are polyclonal antibodies obtained from plasma. These therapeutics use the immune response to deliver protection from infection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will develop COVID-HIG, produced from human plasma with antibodies to SARS-CoV-2, to potentially treat severe infection in hospitalised patients, and also to protect at-risk individuals.

COVID-EIG will be generated using plasma of immunised horses with antibodies to SARS-CoV-2, for the potential treatment of severe hospitalised patients.

Emergent BioSolutions senior vice-president and therapeutics business unit head Laura Saward said: “Emergent is advancing these programs based on our hyperimmune platforms and using existing infrastructure and capabilities that we deployed for our recently completed Phase II clinical trial for our influenza hyperimmune FLU-IGIV to treat patients hospitalized with Influenza A.

“By leveraging our platform and capabilities that are already in place, Emergent is in a state of readiness to develop treatment options for Covid-19 to potentially protect healthcare workers and others on the frontline, as well as treat individuals who have fallen ill.”

The company has already started plasma collection for human and equine platforms. It aims to manufacture clinical material within the coming four to five months and expects to start a clinical study in the third quarter of this year.

The company’s hyperimmune plasma product manufacturing platform was previously used to develop antibody therapeutics for Vaccinia Immune Globulin Intravenous, smallpox vaccine complications and anthrax treatment.

In a separate development, Emergent BioSolutions signed an agreement with Novavax to provide contract development and manufacturing (CDMO) services for the latter’s Covid-19 experimental vaccine candidate.